{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T01:37:01Z","timestamp":1791423421248,"version":"4.3.3"},"reference-count":40,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004731","name":"Natural Science Foundation of Zhejiang Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004731","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.ijantimicag.2019.11.003","type":"journal-article","created":{"date-parts":[[2019,11,21]],"date-time":"2019-11-21T12:09:29Z","timestamp":1574338169000},"page":"105846","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Evaluation of alternative antibiotics for susceptibility of gonococcal isolates from China"],"prefix":"10.1016","volume":"55","author":[{"given":"Fan","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianglin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stijn","family":"van der Veen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2019.11.003_bib0001","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0143304","article-title":"Global estimates of the prevalence and incidence of four curable sexually transmitted infections in 2012 based on systematic review and global reporting","volume":"10","author":"Newman","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.ijantimicag.2019.11.003_bib0002","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1128\/CMR.00010-14","article-title":"Antimicrobial resistance in Neisseria gonorrhoeae in the 21st century: past, evolution, and future","volume":"27","author":"Unemo","year":"2014","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.ijantimicag.2019.11.003_bib0003","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1016\/S1473-3099(13)70143-9","article-title":"Decreased susceptibility to cephalosporins among gonococci: data from the Gonococcal Resistance to Antimicrobials Surveillance Programme (GRASP) in England and Wales, 2007\u20132011","volume":"13","author":"Ison","year":"2013","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijantimicag.2019.11.003_bib0004","first-page":"29","article-title":"Increasing prevalence of Neisseria gonorrhoeae with decreased susceptibility to ceftriaxone and resistance to azithromycin in Hangzhou, China (2015\u201317)","volume":"74","author":"Yan","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2019.11.003_bib0005","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1056\/NEJMc1512757","article-title":"Failure of dual antimicrobial therapy in treatment of gonorrhea","volume":"374","author":"Fifer","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijantimicag.2019.11.003_bib0006","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2018.23.27.1800323","article-title":"Gonorrhoea treatment failure caused by a Neisseria gonorrhoeae strain with combined ceftriaxone and high-level azithromycin resistance, England, February 2018","volume":"23","author":"Eyre","year":"2018","journal-title":"Euro Surveill"},{"key":"10.1016\/j.ijantimicag.2019.11.003_bib0007","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S1473-3099(18)30340-2","article-title":"Genetic characterisation of Neisseria gonorrhoeae resistant to both ceftriaxone and azithromycin","volume":"18","author":"Whiley","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijantimicag.2019.11.003_bib0008","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/S1473-3099(17)30753-3","article-title":"Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis","volume":"18","author":"Tacconelli","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijantimicag.2019.11.003_bib0009","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1056\/NEJMoa1706988","article-title":"Single-dose zoliflodacin (ETX0914) for treatment of urogenital gonorrhea","volume":"379","author":"Taylor","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijantimicag.2019.11.003_bib0010","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1093\/cid\/ciy145","article-title":"Gepotidacin for the treatment of uncomplicated urogenital gonorrhea: a phase 2, randomized, dose-ranging, single-oral dose evaluation","volume":"67","author":"Taylor","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2019.11.003_bib0011","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1093\/cid\/civ478","article-title":"A phase 2 trial of oral solithromycin 1200 mg or 1000 mg as single-dose oral therapy for uncomplicated gonorrhea","volume":"61","author":"Hook","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2019.11.003_bib0012","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1136\/sextrans-2015-052312","article-title":"An outbreak of high-level azithromycin resistant Neisseria gonorrhoeae in England","volume":"92","author":"Chisholm","year":"2016","journal-title":"Sex Transm Infect"},{"key":"10.1016\/j.ijantimicag.2019.11.003_bib0013","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1093\/cid\/cix485","article-title":"Cluster of Neisseria gonorrhoeae isolates with high-level azithromycin resistance and decreased ceftriaxone susceptibility, Hawaii, 2016","volume":"65","author":"Katz","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2019.11.003_bib0014","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1128\/AAC.00036-12","volume":"56","author":"Golparian","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2019.11.003_bib0015","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1136\/sextrans-2012-050604","article-title":"Effectiveness of gentamicin for gonorrhoea treatment: systematic review and meta-analysis","volume":"88","author":"Dowell","year":"2012","journal-title":"Sex Transm Infect"},{"key":"10.1016\/j.ijantimicag.2019.11.003_bib0016","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.ijantimicag.2015.05.007","article-title":"Neisseria gonorrhoeae and fosfomycin: past, present and future","volume":"46","author":"Tesh","year":"2015","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2019.11.003_bib0017","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1093\/jac\/dkh272","article-title":"Activity of ertapenem against Neisseria gonorrhoeae","volume":"54","author":"Livermore","year":"2004","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2019.11.003_bib0018","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0924-8579(01)00355-7","article-title":"GAR-936 (9-t-butylglycylamido-minocycline) susceptibility test development for streptococci, Haemophilus influenzae and Neisseria gonorrhoeae: preliminary guidelines and interpretive criteria","volume":"18","author":"Deshpande","year":"2001","journal-title":"Int J Antimicrob Agents"},{"issue":"Suppl. 1","key":"10.1016\/j.ijantimicag.2019.11.003_bib0019","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/jac\/45.suppl_3.67","article-title":"Anti-gonococcal activity of gemifloxacin against fluoroquinolone-resistant strains and a comparison of agar dilution and Etest methods","volume":"45","author":"Jones","year":"2000","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2019.11.003_bib0020","first-page":"111","article-title":"Treatment of gonorrhoea with single oral doses. Results obtained with doxycycline or rifampicin compared with intramuscular penicillin","volume":"47","author":"van Steenbergen","year":"1971","journal-title":"Br J Vener Dis"},{"key":"10.1016\/j.ijantimicag.2019.11.003_bib0021","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1093\/jac\/dkx147","article-title":"Antimicrobial susceptibility of clinical isolates of Neisseria gonorrhoeae to alternative antimicrobials with therapeutic potential","volume":"72","author":"Lagace-Wiens","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2019.11.003_bib0022","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1093\/jac\/dkw131","article-title":"High prevalence of Neisseria gonorrhoeae with high-level resistance to azithromycin in Hangzhou","volume":"71","author":"Ni","year":"2016","journal-title":"China. J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2019.11.003_bib0023","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1128\/JCM.00100-17","article-title":"Neisseria gonorrhoeae sequence typing for antimicrobial resistance, a novel antimicrobial resistance multilocus typing scheme for tracking global dissemination of N. gonorrhoeae strains","volume":"55","author":"Demczuk","year":"2017","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.ijantimicag.2019.11.003_bib0024","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1093\/cid\/ciu521","article-title":"The efficacy and safety of gentamicin plus azithromycin and gemifloxacin plus azithromycin as treatment of uncomplicated gonorrhea","volume":"59","author":"Kirkcaldy","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2019.11.003_bib0025","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.cmi.2016.09.006","article-title":"Consensus numbering system for the rifampicin resistance-associated rpoB gene mutations in pathogenic mycobacteria","volume":"23","author":"Andre","year":"2017","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2019.11.003_bib0026","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.diagmicrobio.2016.10.022","article-title":"In vitro activity of tigecycline alone and antimicrobial combinations against clinical Neisseria gonorrhoeae isolates","volume":"87","author":"Lee","year":"2017","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2019.11.003_bib0027","doi-asserted-by":"crossref","first-page":"4327","DOI":"10.1128\/AAC.49.10.4327-4334.2005","article-title":"High-level chromosomally mediated tetracycline resistance in Neisseria gonorrhoeae results from a point mutation in the rpsJ gene encoding ribosomal protein S10 in combination with the mtrR and penB resistance determinants","volume":"49","author":"Hu","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2019.11.003_bib0028","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.ijantimicag.2014.10.020","article-title":"Determination of in vitro synergy for dual antimicrobial therapy against resistant Neisseria gonorrhoeae using Etest and agar dilution","volume":"45","author":"Wind","year":"2015","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2019.11.003_bib0029","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1093\/jac\/dkt537","article-title":"Evaluation of the activity of ertapenem against gonococcal isolates exhibiting a range of susceptibilities to cefixime","volume":"69","author":"Quaye","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2019.11.003_bib0030","doi-asserted-by":"crossref","first-page":"3603","DOI":"10.1128\/AAC.00326-12","article-title":"In vitro activity of ertapenem versus ceftriaxone against Neisseria gonorrhoeae isolates with highly diverse ceftriaxone MIC values and effects of ceftriaxone resistance determinants: ertapenem for treatment of gonorrhea?","volume":"56","author":"Unemo","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2019.11.003_bib0031","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/2046-4053-3-104","article-title":"The effectiveness of gentamicin in the treatment of Neisseria gonorrhoeae: a systematic review","volume":"3","author":"Hathorn","year":"2014","journal-title":"Syst Rev"},{"key":"10.1016\/j.ijantimicag.2019.11.003_bib0032","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1016\/S0140-6736(18)32817-4","article-title":"Gentamicin compared with ceftriaxone for the treatment of gonorrhoea (G-ToG): a randomised non-inferiority trial","volume":"393","author":"Ross","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.ijantimicag.2019.11.003_bib0033","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1093\/jac\/dkq476","article-title":"An evaluation of gentamicin susceptibility of Neisseria gonorrhoeae isolates in Europe","volume":"66","author":"Chisholm","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2019.11.003_bib0034","doi-asserted-by":"crossref","first-page":"7518","DOI":"10.1128\/AAC.01907-16","article-title":"Gentamicin susceptibility among a sample of multidrug-resistant Neisseria gonorrhoeae isolates in India","volume":"60","author":"Bala","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2019.11.003_bib0035","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1097\/OLQ.0b013e3181bf575c","article-title":"Neisseria gonorrhoeae antimicrobial susceptibility in Lilongwe, Malawi, 2007","volume":"37","author":"Brown","year":"2010","journal-title":"Sex Transm Dis"},{"key":"10.1016\/j.ijantimicag.2019.11.003_bib0036","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1093\/jac\/dkw102","article-title":"Gentamicin in vitro activity and tentative gentamicin interpretation criteria for the CLSI and calibrated dichotomous sensitivity disc diffusion methods for Neisseria gonorrhoeae","volume":"71","author":"Bala","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2019.11.003_bib0037","doi-asserted-by":"crossref","first-page":"2985","DOI":"10.1128\/jcm.35.11.2985-2988.1997","article-title":"Development of an antimicrobial susceptibility surveillance system for Neisseria gonorrhoeae in Malawi: comparison of methods","volume":"35","author":"Daly","year":"1997","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.ijantimicag.2019.11.003_bib0038","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1093\/jac\/dkt540","article-title":"In vitro synergy testing of novel antimicrobial combination therapies against Neisseria gonorrhoeae","volume":"69","author":"Barbee","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2019.11.003_bib0039","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1097\/OLQ.0000000000000708","article-title":"In vitro synergy testing of gentamicin, an old drug suggested as future treatment option for gonorrhoea, in combination with six other antimicrobials against multidrug-resistant Neisseria gonorrhoeae strains","volume":"45","author":"Singh","year":"2018","journal-title":"Sex Transm Dis"},{"key":"10.1016\/j.ijantimicag.2019.11.003_bib0040","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1128\/AAC.04536-14","article-title":"In vitro activity of fosfomycin alone and in combination with ceftriaxone or azithromycin against clinical Neisseria gonorrhoeae isolates","volume":"59","author":"Hauser","year":"2015","journal-title":"Antimicrob Agents Chemother"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857919303176?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857919303176?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T17:35:25Z","timestamp":1760376925000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857919303176"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["S0924857919303176"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2019.11.003","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of alternative antibiotics for susceptibility of gonococcal isolates from China","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2019.11.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105846"}}